ACV meeting #31, 8 February 2022

The 31st meeting of the Advisory Committee on Vaccines (ACV), February 2022.

Date

8 February 2022

The meeting of the Advisory Committee on Vaccines (ACV).

The committee provided advice on the:

extension of indication for a vaccine with provisional registration for active immunisation to prevent COVID-19 (product name Spikevax; active ingredient Elasomeran; sponsor Moderna Australia Pty Ltd) that had been under evaluation from November 2021.

The committee provided advice on the following safety matter.

Risk of Haemophagocytic lymphohistiocytosis (HLH) associated with Vaxzevria (formerly known as COVID-19 vaccine AstraZeneca)

Members

Membership comprises professionals with expertise in specific scientific, medical or clinical fields, or consumer health issues.

Outcomes

ACV meeting statement, Meeting 31, 8 February 2022

5 April 2022

Meeting statements

Advisory Committee on Vaccines, Meeting 31, 8 February 2022

Topics

Committees and advisory bodies

Meeting of

Advisory Committee on Vaccines (ACV)

Related content

Unique Device Identification (UDI) information session for clinical quality registries

25 May 2026

Webinars

This information session introduces UDI for clinical quality registries. Australia’s UDI framework supports improved identification of medical devices and in vitro diagnostic (IVD) devices.